MedImmune Presents New Pharmaco-Economic Data At American Academy Of Pediatrics Regarding Infants At High Risk For RSV
Oct 29th 2007Drug InformationInfectious Diseases / Bacteria / Viruses
MedImmune announced results from a recent economic analysis of Synagis(R) (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in high- risk infants. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
